His main research concerns Oligonucleotide, Molecular biology, CpG site, Cancer research and Biochemistry. His Oligonucleotide research includes themes of Combinatorial chemistry and Stereochemistry. Ekambar R. Kandimalla has researched Molecular biology in several fields, including Receptor, Peripheral blood mononuclear cell and Cytokine secretion, Immune system.
His work carried out in the field of Receptor brings together such families of science as DNA sequencing and Cell biology. The concepts of his Cancer research study are interwoven with issues in Cancer cell, XIAP and Apoptosis. His study in Biochemistry is interdisciplinary in nature, drawing from both Immune Stimulation and Immunostimulant.
Ekambar R. Kandimalla spends much of his time researching Oligonucleotide, Immunology, Molecular biology, Immune system and Receptor. His work in Oligonucleotide tackles topics such as Stereochemistry which are related to areas like Hydrogen bond. While working on this project, Ekambar R. Kandimalla studies both Molecular biology and CpG site.
He works mostly in the field of Immune system, limiting it down to concerns involving Agonist and, occasionally, Cancer research and Tumor microenvironment. His studies deal with areas such as Toll and Cell biology as well as Receptor. His DNA study incorporates themes from RNase H and Circular dichroism.
His primary scientific interests are in Immunology, Antagonist, Internal medicine, Agonist and Receptor. His work deals with themes such as mdx mouse, Duchenne muscular dystrophy, Dystrophin, Skeletal muscle and Cell biology, which intersect with Immunology. His Cell biology study combines topics from a wide range of disciplines, such as Biochemistry and Antisense Agents.
His Antagonist research is multidisciplinary, incorporating elements of TLR7 and Stimulation. His work in Agonist covers topics such as Tumor microenvironment which are related to areas like Cancer research and CD8. His study looks at the relationship between Receptor and fields such as Inflammation, as well as how they intersect with chemical problems.
His scientific interests lie mostly in Immunology, Receptor, Antagonist, Agonist and TLR9. The study incorporates disciplines such as Dystrophin and ITGA7 in addition to Immunology. His Receptor research incorporates elements of Inflammation and Endocrinology.
The Antagonist study combines topics in areas such as TLR7 and Psoriasis. Ekambar R. Kandimalla has included themes like Clonogenic assay, Gastrointestinal tract, Systemic administration and Crypt in his Agonist study. His TLR9 study spans across into areas like In vivo, Interleukin, Molecular biology, Interferon and Cytokine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics.
Dan C McManus;Charles A Lefebvre;Gabriele Cherton-Horvat;Martine St-Jean.
Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends
Sudhir Agrawal;Ekambar R. Kandimalla;Dong Yu;Lakshmi Bhagat.
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles
Ekambar R. Kandimalla;Lakshmi Bhagat;Daqing Wang;Dong Yu.
Nucleic Acids Research (2003)
Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists
Ekambar R. Kandimalla;Lakshmi Bhagat;Yukui Li;Dong Yu.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships.
Ekambar R Kandimalla;Dong Yu;Qiuyan Zhao;Sudhir Agrawal.
Bioorganic & Medicinal Chemistry (2001)
Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis
Eric C. LaCasse;Gabriele G. Cherton-Horvat;Kimberley E. Hewitt;Lori J. Jerome.
Clinical Cancer Research (2006)
Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways.
Sai Latha Shankar;Sridhar Mani;Kathleen Norman O'Guin;Ekambar R. Kandimalla.
Journal of Neurochemistry (2008)
Medicinal chemistry and therapeutic potential of CpG DNA
Sudhir Agrawal;Ekambar R Kandimalla.
Trends in Molecular Medicine (2002)
Antisense and siRNA as agonists of Toll-like receptors
Sudhir Agrawal;Ekambar R Kandimalla.
Nature Biotechnology (2004)
Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity.
Ekambar R Kandimalla;Lakshmi Bhagat;Dong Yu;Yanping Cong.
Bioconjugate Chemistry (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: